Recent progress on tyrosine kinase 2 JH2 inhibitors

Area of Science:

• Immunology
• Pharmacology

Background:

• Tyrosine kinase 2 (TYK2) is a Janus kinase (JAK) family member regulating pro-inflammatory cytokines like IL-12, IL-23, and IFNα/β.
• Abnormal signaling of IL-12 and IL-23 is implicated in autoimmune diseases.
• Safety concerns with broad-spectrum JAK inhibitors have increased interest in selective TYK2 JH2 inhibitors.

Purpose of the Study:

• To provide an overview of currently available and investigational TYK2 JH2 inhibitors.
• To highlight the therapeutic potential of TYK2 JH2 inhibitors in autoimmune conditions.

Main Methods:

• Literature review of approved and clinical-stage TYK2 JH2 inhibitors.
• Analysis of the role of TYK2 in cytokine signaling pathways.

Main Results:

• Deucravactinib is an approved TYK2 JH2 inhibitor.
• Several other TYK2 JH2 inhibitors, including BMS-986202, NDI-034858, and ESK-001, are in clinical development.

Conclusions:

• TYK2 JH2 inhibitors represent a promising therapeutic strategy for autoimmune diseases.
• Selective inhibition of TYK2 offers a potentially improved safety profile compared to JAK inhibitors.